Cargando…

Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain

PURPOSE: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer’s disease and amyotrophic lateral sclerosis. This first-in-h...

Descripción completa

Detalles Bibliográficos
Autores principales: Koole, Michel, Van Weehaeghe, Donatienne, Serdons, Kim, Herbots, Marissa, Cawthorne, Christopher, Celen, Sofie, Schroeder, Frederick A., Hooker, Jacob M., Bormans, Guy, de Hoon, Jan, Kranz, Janice E., Van Laere, Koen, Gilbert, Tonya M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835181/
https://www.ncbi.nlm.nih.gov/pubmed/32638097
http://dx.doi.org/10.1007/s00259-020-04891-y
_version_ 1783642459748696064
author Koole, Michel
Van Weehaeghe, Donatienne
Serdons, Kim
Herbots, Marissa
Cawthorne, Christopher
Celen, Sofie
Schroeder, Frederick A.
Hooker, Jacob M.
Bormans, Guy
de Hoon, Jan
Kranz, Janice E.
Van Laere, Koen
Gilbert, Tonya M.
author_facet Koole, Michel
Van Weehaeghe, Donatienne
Serdons, Kim
Herbots, Marissa
Cawthorne, Christopher
Celen, Sofie
Schroeder, Frederick A.
Hooker, Jacob M.
Bormans, Guy
de Hoon, Jan
Kranz, Janice E.
Van Laere, Koen
Gilbert, Tonya M.
author_sort Koole, Michel
collection PubMed
description PURPOSE: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer’s disease and amyotrophic lateral sclerosis. This first-in-human positron emission tomography (PET) study evaluated the brain binding of [(18)F]EKZ-001 ([(18)F]Bavarostat), a radiotracer selective for HDAC6, in healthy adult subjects. METHODS: Biodistribution and radiation dosimetry studies were performed in four healthy subjects (2M/2F, 23.5 ± 2.4 years) using sequential whole-body PET/CT. The most appropriate kinetic model to quantify brain uptake was determined in 12 healthy subjects (6M/6F, 57.6 ± 3.7 years) from 120-min dynamic PET/MR scans using a radiometabolite-corrected arterial plasma input function. Four subjects underwent retest scans (2M/2F, 57.3 ± 5.6 years) with a 1-day interscan interval to determine test-retest variability (TRV). Regional volume of distribution (V(T)) was calculated using one-tissue and two-tissue compartment models (1-2TCM) and Logan graphical analysis (LGA), with time-stability assessed. V(T) differences between males and females were evaluated using volume of interest and whole-brain voxel-wise approaches. RESULTS: The effective dose was 39.1 ± 7.0 μSv/MBq. Based on the Akaike information criterion, 2TCM was the preferred model compared to 1TCM. Regional LGA V(T) were in agreement with 2TCM V(T), however demonstrated a lower absolute TRV of 7.7 ± 4.9%. Regional V(T) values were relatively homogeneous with highest values in the hippocampus and entorhinal cortex. Reduction of acquisition time was achieved with a 0 to 60-min scan followed by a 90 to 120-min scan. Males demonstrated significantly higher V(T) than females in the majority of cortical and subcortical brain regions. No relevant radiotracer related adverse events were reported. CONCLUSION: [(18)F]EKZ-001 is safe and appropriate for quantifying HDAC6 expression in the human brain with Logan graphical analysis as the preferred quantitative approach. Males showed higher HDAC6 expression across the brain compared to females.
format Online
Article
Text
id pubmed-7835181
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78351812021-01-29 Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain Koole, Michel Van Weehaeghe, Donatienne Serdons, Kim Herbots, Marissa Cawthorne, Christopher Celen, Sofie Schroeder, Frederick A. Hooker, Jacob M. Bormans, Guy de Hoon, Jan Kranz, Janice E. Van Laere, Koen Gilbert, Tonya M. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer’s disease and amyotrophic lateral sclerosis. This first-in-human positron emission tomography (PET) study evaluated the brain binding of [(18)F]EKZ-001 ([(18)F]Bavarostat), a radiotracer selective for HDAC6, in healthy adult subjects. METHODS: Biodistribution and radiation dosimetry studies were performed in four healthy subjects (2M/2F, 23.5 ± 2.4 years) using sequential whole-body PET/CT. The most appropriate kinetic model to quantify brain uptake was determined in 12 healthy subjects (6M/6F, 57.6 ± 3.7 years) from 120-min dynamic PET/MR scans using a radiometabolite-corrected arterial plasma input function. Four subjects underwent retest scans (2M/2F, 57.3 ± 5.6 years) with a 1-day interscan interval to determine test-retest variability (TRV). Regional volume of distribution (V(T)) was calculated using one-tissue and two-tissue compartment models (1-2TCM) and Logan graphical analysis (LGA), with time-stability assessed. V(T) differences between males and females were evaluated using volume of interest and whole-brain voxel-wise approaches. RESULTS: The effective dose was 39.1 ± 7.0 μSv/MBq. Based on the Akaike information criterion, 2TCM was the preferred model compared to 1TCM. Regional LGA V(T) were in agreement with 2TCM V(T), however demonstrated a lower absolute TRV of 7.7 ± 4.9%. Regional V(T) values were relatively homogeneous with highest values in the hippocampus and entorhinal cortex. Reduction of acquisition time was achieved with a 0 to 60-min scan followed by a 90 to 120-min scan. Males demonstrated significantly higher V(T) than females in the majority of cortical and subcortical brain regions. No relevant radiotracer related adverse events were reported. CONCLUSION: [(18)F]EKZ-001 is safe and appropriate for quantifying HDAC6 expression in the human brain with Logan graphical analysis as the preferred quantitative approach. Males showed higher HDAC6 expression across the brain compared to females. Springer Berlin Heidelberg 2020-07-08 2021 /pmc/articles/PMC7835181/ /pubmed/32638097 http://dx.doi.org/10.1007/s00259-020-04891-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Koole, Michel
Van Weehaeghe, Donatienne
Serdons, Kim
Herbots, Marissa
Cawthorne, Christopher
Celen, Sofie
Schroeder, Frederick A.
Hooker, Jacob M.
Bormans, Guy
de Hoon, Jan
Kranz, Janice E.
Van Laere, Koen
Gilbert, Tonya M.
Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain
title Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain
title_full Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain
title_fullStr Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain
title_full_unstemmed Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain
title_short Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain
title_sort clinical validation of the novel hdac6 radiotracer [(18)f]ekz-001 in the human brain
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835181/
https://www.ncbi.nlm.nih.gov/pubmed/32638097
http://dx.doi.org/10.1007/s00259-020-04891-y
work_keys_str_mv AT koolemichel clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT vanweehaeghedonatienne clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT serdonskim clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT herbotsmarissa clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT cawthornechristopher clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT celensofie clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT schroederfredericka clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT hookerjacobm clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT bormansguy clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT dehoonjan clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT kranzjanicee clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT vanlaerekoen clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain
AT gilberttonyam clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain